Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Massachusetts General Hospital · Seoul National University Hospital · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
580
total citations
- FWCI
- 56.41
- Percentile
- 100%
- References
- 33
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Ceritinib
- Crizotinib
- Medicine
- Anaplastic lymphoma kinase
- Lung cancer
- ALK inhibitor
- Internal medicine
- Chemotherapy
No related works found for this paper.